Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 4 of 4

Full-Text Articles in Entire DC Network

Is Rolapitant Effective In Reducing The Incidence Of Chemotherapy-Induced Nausea And Vomiting (Cinv) In Patients Receiving Emetogenic Chemotherapy?, Brandon E. Eberts Jan 2017

Is Rolapitant Effective In Reducing The Incidence Of Chemotherapy-Induced Nausea And Vomiting (Cinv) In Patients Receiving Emetogenic Chemotherapy?, Brandon E. Eberts

PCOM Physician Assistant Studies Student Scholarship

Objective: The objective of this selective EBM review is to determine whether or not rolapitant is safe and effective in reducing the incidence of chemotherapy induced nausea and vomiting (CINV) in patients receiving emetogenic chemotherapy.

Study Design: This review is based on three randomized controlled trials (RCTs) all published in 2015. The studies compared the safety and efficacy of rolapitant in decreasing the incidence of CINV.

Data Sources: All articles used were published in English, in peer-reviewed journals, and found using PubMed and the Cochrane Review database.

Outcomes Measured: All included studies measured the safety and …


Are Five Sessions Of Individual Based Art Therapy Effective In Reducing Emotional Problems In Swedish Women With Nonmetastatic Breast Cancer Receiving Radiation Therapy?, Sarah C. Hayes Jan 2017

Are Five Sessions Of Individual Based Art Therapy Effective In Reducing Emotional Problems In Swedish Women With Nonmetastatic Breast Cancer Receiving Radiation Therapy?, Sarah C. Hayes

PCOM Physician Assistant Studies Student Scholarship

OBJECTIVE: The objective of this selective EBM review is to determine “Are five sessions of individual based art therapy effective in reducing emotional problems in Swedish women with nonmetastatic breast cancer receiving radiation therapy?”

STUDY DESIGN: This review is based on three randomized control studies, two which were published in 2009 and one that was published in 2006.

DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and found using PubMed, Ebscohost, and Cochrane Review databases.

OUTCOMES MEASURED: For all studies, factors pertaining to emotional problems were measured through self-assessment questionnaires.

RESULTS: …


Is Necitumumab An Effective Addition To Traditional Chemotherapeutic Regiments When Treating Stage Iv Lung And Colon Cancer?, J. Ross Hosford Jan 2017

Is Necitumumab An Effective Addition To Traditional Chemotherapeutic Regiments When Treating Stage Iv Lung And Colon Cancer?, J. Ross Hosford

PCOM Physician Assistant Studies Student Scholarship

Objective: The objective of this selective EBM review is to determine whether or not Necitumumab is an effective add on treatment to traditional chemotherapy regimes when treating stage IV lung or colon cancer.

Study Designs: Review of two open label, randomized, controlled phase III trials and one single arm multicenter phase II study.

Outcomes Measured: Objective tumor response rate was measured for patients with colon cancer. Overall survival rate and length of survival were measured for patients with lung cancer. This was measured in Kapler Meier Methodology.

Results: For two trials the addition of Necitumumab improved …


Is Combination Nivolumab And Ipilimumab Safe And Effective In Patients With Melanoma?, Jacob L. Toscano Jan 2017

Is Combination Nivolumab And Ipilimumab Safe And Effective In Patients With Melanoma?, Jacob L. Toscano

PCOM Physician Assistant Studies Student Scholarship

Objective: The objective of this selective EBM review is to determine whether or not combination nivolumab and ipilimumab is safe and effective in patients with melanoma.

Study design: Review of two randomized controlled trials (RCTs) published in 2015, and one cohort study published in 2013.

Data Sources: All of the articles were published in English language, peer reviewed journals and were found using PubMed and Cochrane databases.

Outcomes Measured: The safety of combination nivolumab and ipilimumab was measured by treatment-related grade 3 or 4 adverse effects. The effectiveness was measured by progression-free survival, which is based …